Anthropic adjusts its IPO: investors want to value it at $1.5-1.6 trillion, not close to 2

By The Wall Street Journal · November 2, 2026.

Large institutional investors planning to buy shares in Anthropic's IPO have told the company and its advisers that its valuation should be between $1.5 trillion and $1.6 trillion (trillions on the short scale used in English). The WSJ reports this, citing people familiar with the matter. The IPO (initial public offering, the first sale of shares to the public) is expected later this month.

The figure is well below the roughly $2 trillion that had been floated in recent months, according to the same outlet. The reason, again according to the WSJ, is last week's sharp drop in tech stocks, which has made investors more cautious. The article we had access to is a short excerpt, so we do not know further details: neither the size of the offering, nor the price per share, nor whether Anthropic will accept that range.

The numbers need some context. Even at the low end, this is a company valued at more than one and a half trillion dollars, a figure that would have seemed implausible for an AI model company just a few years ago. The "cut" is between 20% and 25% from the $2 trillion benchmark: significant, but not a fundamental change.

**Our take.** This episode says more about the market than about Anthropic. An IPO valuation does not measure what the model can do, but how much investors are willing to pay today for future cash flows in a particular mood. That a one-week shake-up in tech stocks can move the benchmark price by hundreds of billions shows how much these figures rest on expectations rather than proven results.

In the short term, this is a useful reminder against euphoria: AI valuations are sensitive to sentiment and can correct quickly. A somewhat more restrained IPO is not bad news; it tends to be healthier, leaves room for gains for new shareholders and reduces the risk of an ugly drop after the debut. Generally, IPOs that start at demanding prices tend to pay for it later.

In the long term, what matters is something else: that the incoming capital funds compute, research and deployment in areas of real impact, such as biomedicine, where the promise of eradicating diseases and of abundance is at stake. A market that is more demanding on price may, paradoxically, force companies to prove that value sooner. There is also a governance question that will not go away: a publicly traded Anthropic will answer to shareholders quarter after quarter, and it will be worth watching how it balances that pressure with its safety message.

The final date and price will show whether investors get their way. Until then, the figures should be treated for what they are: a negotiation, not a verdict.